Environmental, Social And Governance Report

Overview

The report presents China Resources Pharmaceutical Group Limited and its subsidiaries’ 2025 sustainability performance across expanded reporting boundaries, including newly consolidated subsidiaries such as Nigale Biotechnology. It identifies 26 sustainability topics, including 11 double-materiality topics, and places ESG oversight with the Board of Directors. Key reported outcomes include 84,111 employees, 740,871.55 tCO2e of total CO2 emissions, and 172,130.25 tCO2e of Scope 1 emissions.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services

Overview